Osteoporosis Prevention: A Nutritional and Natural Health Reference
1. Definition, Presentation, and Body Systems Involved
Osteoporosis is a skeletal disorder characterized by low bone mass and deterioration of bone microarchitecture, leading to increased bone fragility and a higher risk of fractures. This "silent" disease significantly increases the risk of fractures, scoliosis, and pain, and according to the World Health Organization (WHO), osteoporosis is defined based on a T-score below −2.5 standard deviations (SD) at the lumbar spine, hip, or mid-radius as measured by dual-energy X-ray absorptiometry (DXA).
Osteoporosis — related to various factors including menopause and aging — is the most common chronic metabolic bone disease characterized by increased bone fragility, and although it is seen in all age groups, genders, and races, it is more common in Caucasians, older people, and women. With an aging population and longer life span, osteoporosis is increasingly becoming a global epidemic, and it is currently estimated that more than 200 million people suffer from the condition.
1.1 Bone Architecture and Tissue
Bone consists of dense outer cortical bone and spongy inner cancellous bone, both having distinct properties that work together to maintain bone strength. They are made up of cells — including osteocytes, osteoclasts, osteoblasts, and stem cells — and bone matrix, which is composed of calcium, phosphorus, inorganic salts, and bone collagen. Osteoclasts resorb bone, whereas osteoblasts form new bone; the antagonistic actions of these two cell types occur constantly in the body in order to maintain bone health and structural integrity of the skeleton, a process termed bone remodeling or bone turnover.
The imbalance between bone resorption and bone formation results in the loss of bone density and disruption of the structural integrity of bone tissue, particularly affecting the trabecular (spongy) bone found in areas such as the vertebrae, hips, and wrists.
1.2 The Remodeling Cycle and Its Disruption
Bone remodeling has four sequential phases: activation precedes resorption, which precedes reversal, which precedes the formation of a new osteon — and this process is the same in both cortical and trabecular (cancellous) bone. In most individuals, bone mass peaks in the third decade, after which bone resorption exceeds bone formation. Failure to reach a normal peak bone mass or acceleration of bone loss can lead to osteoporosis.
The underlying molecular mechanisms of osteoporosis are believed to involve increased activity of osteoclasts, decreased activity of osteoblasts, or both, which leads to an imbalance in the bone remodeling process with accelerated bone resorption and attenuated bone formation. The RANK/RANKL/OPG signaling pathway is central to the regulation of osteoclastogenesis and bone remodeling. RANKL (receptor activator of nuclear factor kappa-B ligand) is produced by osteoblasts and bone marrow stromal cells and binds to RANK receptors on osteoclast precursors, stimulating their differentiation into mature, bone-resorbing osteoclasts. Osteoprotegerin (OPG), also produced by osteoblasts, acts as a decoy receptor that binds RANKL, preventing it from activating RANK and thus inhibiting osteoclastogenesis. In osteoporosis, the balance between RANKL and OPG is disrupted — either due to increased RANKL or decreased OPG levels — resulting in excessive osteoclast activity and bone resorption.
Additionally, remodeling processes maintain calcium and phosphate homeostasis by targeted release and incorporation from and into the bone matrix. Important effector proteins released by osteocytes that modulate osteoblast and osteoclast formation are SOST, an inhibitor of the Wnt signaling pathway, and RANKL.
Histologic specimens from osteoporotic bone demonstrate markedly thinned trabeculae, decreased osteon size, and enlarged Haversian canals and marrow spaces.
1.3 Body Systems Involved
An understanding of the pathophysiology of osteoporosis involves an array of interconnected models, including the osteoimmunological model, the gut microbiome model, and the cellular senescence model. The musculoskeletal system provides the primary site of pathology, but the endocrine system — particularly estrogen, parathyroid hormone (PTH), and active vitamin D (calcitriol) — plays a critical regulatory role. Women experience disproportionately more bone fragility than men, primarily due to the natural decline in estradiol (a hormone that inhibits bone resorption) that occurs at menopause. Individuals older than 65 years also show decreased calcium absorption and reduced production of calcitriol (the active form of vitamin D).
Inflammatory cytokines also play a significant role in the pathophysiology of osteoporosis. The gastrointestinal system governs absorption of bone-essential nutrients including calcium, magnesium, and vitamins D and K. The renal system regulates calcium and phosphate homeostasis and activates vitamin D precursors to their biologically active forms.
2. Contributing and Associated Factors
2.1 Non-Modifiable Risk Factors
Non-modifiable risk factors include those associated with genetics, race, gender, age, height, family history, and pregnancy and lactation status. The presence of fragility fracture in a first-degree relative is a strong indicator that genetic factors may contribute to the development of osteoporosis. It is well established that both peak bone mass and the ensuing bone loss are genetically predetermined; according to twin studies, the heritability of bone mineral density ranges from 50% to 85%, with the axial skeleton showing the highest impact.
Epidemiological investigations have identified several major associated factors, including age, sex, body mass index, physical inactivity, smoking, excessive alcohol consumption, and dietary factors such as low calcium and vitamin D intake. Notably, age and sex are two of the most significant factors, with the prevalence of osteoporosis increasing with advanced age and being much higher in women, particularly after menopause.
Major risk factors for osteoporotic fracture include age, sex, body mass index (BMI), fracture history, smoking, glucocorticoid medication history, rheumatoid arthritis, diseases that can cause secondary osteoporosis, and bone mineral density.
2.2 Secondary Causes: Medications and Disease States
Previous studies confirm that the use of glucocorticoids is a common secondary cause of osteoporosis among adults, especially patients with rheumatoid arthritis. Findings from Mendelian randomization studies revealed that conditions including rheumatoid arthritis, inflammatory bowel disease, altered sex hormone-binding globulin, depression, and non-alcoholic fatty liver disease are associated with osteoporosis risk.
2.3 Modifiable Lifestyle Risk Factors
Management strategies for osteoporosis focus on reducing modifiable risk factors such as poor nutrition, insufficient physical activity, smoking, and heavy alcohol consumption.
Smoking: The negative impact of smoking on bone health reaches beyond increased risk of osteoporosis and fracture. Smoking has been suggested to worsen the prognosis of surgical fracture procedures and to prolong healing time. In a systematic review including 19 cohort studies, it was concluded that smoking significantly increased the risk of nonunion of fractures overall. Cortical thickness measured by peripheral quantitative computed tomography (pQCT) was 2.9% to 4.0% lower in smokers due to greater endosteal circumference. Bone mineral density at the hip was −4.7% lower among current smokers compared to never smokers.
Alcohol: The effects of alcohol consumption on the risk of osteoporotic fractures are mediated through both direct, endocrine, metabolic, and nutritional effects that converge on the bone. In a subset of patients, the consequences of skeletal fragility are further exacerbated by an increased risk of falling due to intoxication and/or neuropathy.
Physical Activity: Lifestyle choices influence 20–40% of adult peak bone mass. Therefore, optimization of lifestyle factors known to influence peak bone mass and strength is an important strategy aimed at reducing risk of osteoporosis or low bone mass later in life.
3. Nutrients Studied in Relation to Osteoporosis Prevention
3.1 Calcium
The FDA has approved a health claim for the use of supplements containing calcium and vitamin D to reduce the risk of osteoporosis. However, not all research supports this claim; observational evidence is mixed on the link between calcium intakes and bone health outcomes.
Conclusions from systematic reviews indicate that calcium, or calcium in combination with vitamin D supplementation, was effective in the preventive treatment of osteoporosis in people aged 50 years or older, with the best effect seen with minimum doses of 1,200 mg of calcium and 800 IU of vitamin D.
Clinical guidelines recommend that postmenopausal women should be counseled to maintain adequate dietary intake of calcium (1,000 mg to 1,200 mg per day) and vitamin D (600 to 800 IU per day).
Individuals older than 65 years show decreased calcium absorption and reduced production of calcitriol (the active form of vitamin D), increasing nutritional requirements.
An expert panel convened by the National Osteoporosis Foundation and American Society for Preventive Cardiology determined, on the basis of moderate-quality evidence, that calcium intakes with or without vitamin D from foods or supplements neither increase nor decrease the risk of cardiovascular disease or cardiovascular mortality.
Evidence strength: Moderate-to-strong evidence from multiple RCTs and meta-analyses supports the role of calcium (particularly combined with vitamin D) in reducing fracture risk in older adults with nutritional insufficiency. Evidence is mixed in community-dwelling adults without deficiency.
3.2 Vitamin D
The U.S. Preventive Services Task Force (USPSTF) evaluated 11 randomized clinical trials of vitamin D and/or calcium supplementation in a total of 51,419 healthy, community-dwelling adults aged 50 years and older who did not have osteoporosis, vitamin D deficiency, or prior fractures. It concluded that the current evidence was insufficient to evaluate the benefits and harms of supplementation to prevent fractures. In addition, the USPSTF recommended against supplementation with 400 IU or less of vitamin D and 1,000 mg or less of calcium to prevent fractures in this population, but it could not determine the balance of benefits and harms from higher doses.
A calcium intake below the recommended level was observed in 56% of study participants, and 98% did not reach the estimated average requirement for vitamin D. Calcium and vitamin D are well known to be key bone nutrients, and relatively high combined intakes can lead to a modest fracture risk reduction, especially in individuals with an insufficiency for these nutrients.
Evidence strength: Evidence for vitamin D supplementation specifically, absent confirmed deficiency, remains insufficient or mixed per the USPSTF. It is better established in populations with frank deficiency or limited sun exposure.
3.3 Vitamin K
The predominant dietary form, phylloquinone or vitamin K1, is found in plants and green vegetables, whereas menaquinone (vitamin K2) is endogenously synthesized by intestinal bacteria and includes several subtypes that differ in side chain length. Vitamin K is required for osteocalcin carboxylation, which in turn regulates bone mineral accretion; it also appears to promote the transition of osteoblasts to osteocytes and to limit the process of osteoclastogenesis.
Epidemiological studies and clinical trials consistently indicate that vitamin K has a positive effect on bone mineral density and decreases fracture risk. Typical dietary intakes of vitamin K are below the levels associated with better bone mineral density.
In clinical studies, vitamin K2 maintains lumbar bone mineral density, reduces age-related osteoporotic fractures, reduces glucocorticoid-induced osteoporotic vertebral fractures, and increases metacarpal bone mineral density. A three-year RCT showed that supplementing vitamin K2 (MK-7) at 180 μg/day reduced the usual age-related decline in BMD in the lumbar spine and femoral neck but not the total hip. Vitamin K2 (MK-7) also prevented the loss in vertebral height in the lower thoracic spine.
Supplementation with low-dose vitamin K1 (500 μg/day) for 3 years did not improve bone density in the treatment group, and another study in which vitamin K1 was used for two years resulted in no significant change in bone density compared to placebo.
A systematic review and meta-analysis including postmenopausal and osteoporotic females found that the odds ratios of any fracture were lower for vitamin K as compared to control (OR 0.42 [95% CI 0.27–0.66] for vertebral fractures and OR 0.44 [95% CI 0.23–0.88] for clinical fracture). For bone mineral density, a meta-analysis of pooled interventional studies suggested a non-significant association between vitamin K use and improvement in femoral BMD. Vitamin K decreases general fracture risk and may be an option to counter bone loss disorders, but insufficient evidence exists regarding significant impact on femoral neck BMD, and further studies are required to establish the therapeutic value of vitamin K supplementation for osteoporosis.
Vitamin K supplementation is not globally recommended to counteract post-menopausal bone loss, although an exception is Japan, where it has already been approved for the prevention and treatment of osteoporosis.
Evidence strength: Moderate for K2 (MK-7) forms on fracture risk reduction; weaker for effects on bone mineral density, particularly at the femoral neck. K1 evidence is inconsistent. Most studies are limited by short duration, small populations, and variable methodology.
3.4 Magnesium
Insufficiencies of magnesium, silicon, vitamin K, and boron are rarely explained to physicians, although the more common insufficiencies of calcium, vitamin D, and exercise are increasingly recognized as contributors to bone health.
Research in animal models demonstrated that combining magnesium and boron supplementation outperformed individual intake, implying their promising efficacy in maintaining bone health during menopause. Further large-scale research and clinical trials should be conducted to confirm the collaborative impact of magnesium and boron and to determine safe and optimal doses and regimens. Evidence in humans for magnesium specifically remains largely observational and at a preliminary stage; large-scale, well-controlled human RCTs are lacking.
Evidence strength: Preliminary. Observational associations between low magnesium intake and reduced bone mineral density exist, but human intervention trial evidence is limited. Animal studies are promising but cannot be directly extrapolated to humans.
3.5 Omega-3 Fatty Acids
Emerging evidence from epidemiological and experimental studies suggests that omega-3 fatty acids may positively influence bone metabolism, potentially enhancing bone formation and inhibiting bone resorption through mechanisms involving calcium balance, inflammatory cytokines, and prostaglandins.
A recent review indicates that fish has a positive impact on BMD mainly due to the anti-inflammatory effect of omega-3 fatty acids. In particular, DHA is positively related with bone mineral accumulation and with peak BMD in young men. Furthermore, omega-3 fatty acids favor duodenal calcium absorption and lead to decreased calcium excretion.
In a NHANES cross-sectional study, participants in the highest quartile of omega-3 intake exhibited a 32% reduction in the odds of osteoporosis compared to those in the lowest quartile, after adjustment for age, sex, and race. This study demonstrated a significant inverse relationship between dietary omega-3 fatty acid intake and osteoporosis risk, although further longitudinal studies are needed to confirm these findings and refine dietary recommendations for osteoporosis prevention.
Evidence strength: Preliminary to moderate. Cross-sectional associations are promising, but causal evidence from longitudinal RCTs remains limited. Findings are primarily observational or derived from animal studies.
3.6 Dietary Protein
Dietary protein is one of the most important nutritional considerations as it affects bone mineral density, trabecular and cortical microstructure, and bone strength. When calcium intake is sufficient, higher dietary protein intake is associated with lower risk of fracture.
Dietary protein is believed to play a role in combating osteoporosis. Protein intake is important for bone health via the up-regulation of anabolic hormones, improvements in intestinal calcium absorption, and by maintaining muscle mass and muscle strength.
Dairy products are a valuable source of calcium and high-quality protein. Dairy product consumption, particularly fermented dairy products, is associated with a lower risk of hip fracture, and vegan diets are associated with increased fracture risk.
Evidence strength: Moderate. Meta-analyses support an association between adequate protein intake and lower fracture risk, particularly when calcium intake is adequate. The relationship between very high protein intake and bone health is less certain.
3.7 Boron
Silicon, vitamin K, and boron are among the lesser-known nutrients whose insufficiencies are rarely communicated to clinicians, despite their potential roles in bone health. Boron has been studied in relation to calcium and magnesium metabolism, and preliminary evidence from animal studies suggests it may modulate estrogen activity and bone turnover, particularly during menopause. Combining boron and magnesium supplementation outperformed individual supplementation in animal models, but further large-scale clinical trials are needed to confirm these effects and determine optimal dosing in humans.
Evidence strength: Primarily animal/in-vitro and preliminary observational data in humans. Clinical evidence from human RCTs is insufficient to draw firm conclusions.
3.8 Vitamin C
Vitamin C is essential for the formation of collagen and for fracture healing. The evidence for supplemental vitamin C in the management of osteoporosis is weak, but increased bone mineral density has been noted in postmenopausal women taking vitamin C supplements.
Evidence strength: Weak to preliminary. Evidence is largely observational, and intervention trial data specific to bone outcomes are limited.
4. Herbs and Phytochemicals Studied in Relation to Osteoporosis
4.1 Soy Isoflavones and Red Clover (Trifolium pratense)
Traditional Use
There is evidence that diets containing high levels of phytoestrogenic isoflavones are associated with a low incidence of osteoporosis and menopausal symptoms. Plant extracts containing high levels of isoflavones, such as Red clover (Trifolium pratense L.), have been traditionally used to reduce menopausal symptoms. Soy-rich diets have long been a feature of traditional East Asian nutrition, and epidemiological observations linking soy intake with lower rates of menopausal bone loss gave rise to early interest in isoflavone supplementation. Because of their selective estrogenic-like activity, soy and red clover have been hypothesized to have a positive effect on bone mineral density as women age.
Scientific Evidence
Recent literature explores the role of phytoestrogens in the prevention and treatment of osteoporosis, focusing on soy isoflavones, red clover, and other plants such as Epimedium, hops, fennel, and prunes. Clinical trials examining the effects of these phytoestrogens on bone mineral density, bone turnover markers, and osteoporotic fracture risk have found that phytoestrogens, particularly those derived from soy and red clover, may help improve bone health, alleviate menopausal symptoms, and reduce the risk of fractures.
A systematic review of randomized controlled trials on phytoestrogens during the menopause transition included 23 eligible studies with 3,494 participants enrolled, most using a double-blind, placebo-controlled design. Different types of soy isoflavone extracts, including genistein extracts (either alone or in combination with daidzein), dietary products containing phytoestrogens, and red clover extracts were used in the interventions, with durations ranging from 7 weeks to 3 years. The authors concluded that isoflavones probably have beneficial effects on bone health in menopausal women, though conflicting reports exist regarding the magnitude of changes.
In animal model research, ovariectomy reduced bone mineral content, femoral weight, femoral density, mechanical strength of the tibia, and increased osteoclast numbers in femur sections. Treatment with red clover isoflavones significantly increased bone mineral content, mechanical strength of the tibia, femoral weight, and femoral density, and significantly reduced the number of osteoclasts compared with ovariectomized control rats. These findings suggest that red clover isoflavones are effective in reducing bone loss induced by ovariectomy, probably by reducing bone turnover via inhibition of bone resorption. However, these are animal studies and cannot be directly extrapolated to human clinical outcomes.
Red clover isoflavones have more evidence-based studies than most herbal medicinal products, although the literature is hampered by differences in methodologies, making direct comparison between studies difficult.
Evidence strength: Moderate for a beneficial effect on bone turnover markers and bone mineral density in menopausal women, with stronger pre-clinical evidence. Fracture reduction has not been definitively demonstrated in large-scale human RCTs. Evidence for red clover in humans is more limited than for soy isoflavones.
4.2 Strontium Salts
Clinical studies in adults with osteoporosis have demonstrated that the strontium salt strontium ranelate reduces the incidence of fractures (both vertebral and non-vertebral) and increases bone mass and bone mineral density. The recommended dose for treatment of osteoporosis was 2 g of strontium ranelate daily, taken as an oral suspension, used in clinical trials for three years with long-term follow-up studies lasting 5 to 10 years. Strontium ranelate was at one point withdrawn from treatment due to reports of serious side effects, including cardiovascular risk and non-fatal myocardial infarctions. The European Medicines Agency (EMA) subsequently issued an overview describing how strontium ranelate can be used only with many restrictions.
Strontium can be incorporated into bone cells, increasing their density and reducing the risk of developing osteopenia and osteoporosis. However, intravenous administration of high-dose strontium contributes to hypocalcemia caused by increased renal excretion of calcium ions.
Evidence strength: Strong evidence for the pharmaceutical form (strontium ranelate) in reducing fracture risk, but its use is significantly restricted due to serious cardiovascular adverse events. Evidence for over-the-counter strontium salts (e.g., strontium citrate) in nutritional contexts is considerably weaker, and these forms have not been subject to the same large-scale clinical trials.
5. Dietary Patterns and Lifestyle Factors
5.1 The Mediterranean Diet
A traditional Mediterranean diet is characterized by a high intake of vegetables, legumes, fruits, nuts, cereals, and unsaturated fats, especially olive oil; a low intake of saturated fats, meat, and poultry; a moderate to high intake of fish; and a low to moderate intake of dairy products, usually in the form of cheese or yogurt.
Substantial research evidence demonstrates that dietary intervention models based on holistic dietary patterns exert positive effects on skeletal health through multi-target mechanisms. Multiple studies have confirmed significant associations between various dietary patterns and bone health indicators; a meta-analysis revealed that the Mediterranean diet was closely associated with improved bone mineral density, while a systematic review demonstrated its significant protective effect against fracture risk.
Mediterranean diet adherence has proven to be beneficial to bone mineral density, muscle mass, and physical function, and this diet is proposed as a therapeutic tool that could slow the onset of osteoporosis. However, there is doubt about the interaction between the Mediterranean diet, strength, and fracture risk, and the results of research examining the amount of extra-virgin olive oil, fruits, vegetables, and fish consumed remain controversial.
A Mediterranean-type diet and the daily consumption of 2 to 3 dairy products are recommended; together, these provide the calcium and high-quality protein required to maintain a normal calcium-phosphorus balance and bone metabolism. Dairy products — mainly fermented — are consumed daily, fish at least twice a week, and meat only occasionally. The Mediterranean diet is rich in antioxidant micronutrients, vitamins C and E, carotenoids, polyphenols, and omega-3 fatty acids.
5.2 Broader Dietary Pattern Considerations
Other dietary factors associated with reduced fracture risk include at least 5 servings per day of fruits and vegetables, regular tea drinking, adherence to a Mediterranean diet, and other dietary patterns that provide fibers, polyphenols, and fermented dairy products. Such dietary patterns may confer health benefits through their effect on gut microbiota composition and/or function.
Research further indicates that adherence to healthy dietary patterns effectively reduces the risk of low bone mineral density, with even more pronounced improvements in bone mineral density and content when combined with physical activity.
5.3 Physical Activity and Exercise
The results of systematic reviews indicate that lifestyle interventions including exercise and daily calcium and vitamin D supplementation are beneficial for improving bone health in women at high risk of osteoporosis.
According to a systematic review, physical activities probably have significant clinical advantages in preventing osteoporosis in older adults, especially activities that include a variety of exercises and resistance training performed regularly (at least 2 to 3 times a week) for more than 60 minutes.
In international guidelines and recommendations for osteoporosis management, exercising is considered to be one of the best practices for managing osteoporosis and preventing fractures.
5.4 Smoking Cessation and Alcohol Moderation
Although many strong risk factors for osteoporosis — such as family history, fracture history, and age — are not modifiable, a number of important risk factors are potential targets for intervention. Simple, non-pharmacological intervention in patients at increased risk of osteoporotic fractures could include reduction of excessive alcohol intake, smoking cessation, adequate nutrition, patient education, daily physical activity, and a careful review of medications that could increase the risk of falls and fractures.
5.5 Peak Bone Mass Across the Lifespan
Lifestyle choices influence 20–40% of adult peak bone mass. Therefore, optimization of lifestyle factors known to influence peak bone mass and strength is an important strategy aimed at reducing risk of osteoporosis or low bone mass later in life.
Efforts to prevent bone loss and osteoporosis should start with proper education about a healthy lifestyle, including optimal calcium and vitamin D and exercise in adolescence. This education should continue throughout life, with emphasis during times of increased bone loss such as the menopause transition.
References
- Osteoporosis pathogenesis and treatment — PMC/NIH
- Osteoporosis — StatPearls, NCBI Bookshelf (NIH)
- The Epidemiology and Pathogenesis of Osteoporosis — Endotext, NCBI Bookshelf
- Osteoporosis: Pathophysiology and therapeutic options — PMC
- An overview and management of osteoporosis — PMC/NIH
- Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics — PMC
- Pathophysiology — International Osteoporosis Foundation
- Demystifying the Risk Factors and Preventive Measures for Osteoporosis — PMC
- Mendelian randomization studies of risk and protective factors for osteoporosis: systematic review and meta-analysis — PMC
- Prevalence of osteoporosis and associated factors among Chinese adults — PMC
- Global, regional prevalence, and risk factors of osteoporosis: systematic review and meta-analysis — Osteoporosis International, Springer
- Calcium — NIH Office of Dietary Supplements
- Vitamin D — NIH Office of Dietary Supplements
- The use of calcium and vitamin D in the management of osteoporosis — PMC
- Food-based calcium or vitamin D or both for osteoporosis in postmenopausal women — PMC (Cochrane)
- Vitamin D, Calcium, or Combined Supplementation for Prevention of Falls and Fractures — USPSTF
- Vitamin K and osteoporosis: Myth or reality? — Metabolism: Clinical and Experimental
- Bone health and osteoporosis: the role of vitamin K — PubMed
- Vitamins K1 and K2: The Emerging Group of Vitamins Required for Human Health — PMC
- Influence of Vitamin K on Bone Mineral Density and Osteoporosis — PMC
- Effect of Vitamin K on Bone Mineral Density and Fracture Risk in Adults: Systematic Review and Meta-Analysis — MDPI Biomedicines
- Essential Nutrients for Bone Health and a Review of their Availability in the Average North American Diet — PMC
- The Influence of Strontium on Bone Tissue Metabolism and Its Application in Osteoporosis Treatment — PMC
- Combined Supplementation of Magnesium and Boron Ameliorate Menopause-Associated Osteogenic Disturbances in Ovariectomized Rats — PubMed
- A systematic review of the effectiveness of lifestyle interventions for improving bone health in women at high risk of osteoporosis — PubMed
- A review of lifestyle, smoking and other modifiable risk factors for osteoporotic fractures — PMC
- The National Osteoporosis Foundation's position statement on peak bone mass development and lifestyle factors — Osteoporosis International, Springer
- Phytoestrogens in osteoporosis — PubMed
- Effects of phytoestrogenic isoflavones from red clover on experimental osteoporosis — PubMed
- Effects of phytoestrogens on bone mineral density during the menopause transition: a systematic review of RCTs — PubMed
- Effect of an isoflavones-containing red clover preparation on bone metabolism in ovariectomized rats — PMC
- The Influence of the Mediterranean Dietary Pattern on Osteoporosis and Sarcopenia — PMC
- Adherence to a Mediterranean Diet and Bone Mineral Density in Spanish Premenopausal Women — PMC
- The association between dietary omega-3 intake and osteoporosis: a NHANES cross-sectional study — PMC
- Protein intake and bone mineral density: Cross-sectional relationship and longitudinal effects in older adults — PMC
- Nutrition and Osteoporosis Prevention — Current Osteoporosis Reports, PMC
- The role of fat-soluble vitamins A, D, E, and K in osteoporosis: mechanisms, interactions, and evidence — PMC
- The Role of Magnesium, Zinc, and Strontium in Osteoporotic Fracture Repair — PMC
- Overview of osteoporosis: pathophysiology and determinants of bone strength — PMC
- Dietary recommendations in the prevention and treatment of osteoporosis — ScienceDirect (Joint Bone Spine)
- The impact of high-quality dietary patterns on the prevention of osteoporosis: a meta-analysis — PMC
Go back